Mechanisms of Berberine for the Treatment of Atherosclerosis Based on Network Pharmacology

Atherosclerosis is a common metabolic disease characterized by lipid metabolic disorder. The processes of atherosclerosis include endothelial dysfunction, new endothelial layer formation, lipid sediment, foam cell formation, plaque formation, and plaque burst. Owing to the adverse effects of first-l...

Full description

Bibliographic Details
Main Authors: Xuejiao Xie, Xingyu Ma, Siyu Zeng, Wansi Tang, Liucheng Xiao, Chenggong Zhu, Rong Yu
Format: Article
Language:English
Published: Hindawi Limited 2020-01-01
Series:Evidence-Based Complementary and Alternative Medicine
Online Access:http://dx.doi.org/10.1155/2020/3568756
id doaj-e2cb41b9e014420e85dc9043b70258c5
record_format Article
spelling doaj-e2cb41b9e014420e85dc9043b70258c52020-11-25T02:40:35ZengHindawi LimitedEvidence-Based Complementary and Alternative Medicine1741-427X1741-42882020-01-01202010.1155/2020/35687563568756Mechanisms of Berberine for the Treatment of Atherosclerosis Based on Network PharmacologyXuejiao Xie0Xingyu Ma1Siyu Zeng2Wansi Tang3Liucheng Xiao4Chenggong Zhu5Rong Yu6Department of Zhongjing Theory, College of Chinese Medicine, Hunan University of Chinese Medicine, Changsha 410208, ChinaDepartment of Zhongjing Theory, College of Chinese Medicine, Hunan University of Chinese Medicine, Changsha 410208, ChinaDepartment of Zhongjing Theory, College of Chinese Medicine, Hunan University of Chinese Medicine, Changsha 410208, ChinaDepartment of Zhongjing Theory, College of Chinese Medicine, Hunan University of Chinese Medicine, Changsha 410208, ChinaDepartment of Zhongjing Theory, College of Chinese Medicine, Hunan University of Chinese Medicine, Changsha 410208, ChinaDepartment of Zhongjing Theory, College of Chinese Medicine, Hunan University of Chinese Medicine, Changsha 410208, ChinaCollege of Chinese Medicine, Hunan University of Chinese Medicine, Changsha 410208, ChinaAtherosclerosis is a common metabolic disease characterized by lipid metabolic disorder. The processes of atherosclerosis include endothelial dysfunction, new endothelial layer formation, lipid sediment, foam cell formation, plaque formation, and plaque burst. Owing to the adverse effects of first-line medications, it is urgent to discover new medications to deal with atherosclerosis. Berberine is one of the most promising natural products derived from traditional Chinese medicine. However, the panoramic mechanism of berberine against atherosclerosis has not been discovered clearly. In this study, we used network pharmacology to investigate the interaction between berberine and atherosclerosis. We identified potential targets related to berberine and atherosclerosis from several databases. A total of 31 and 331 putative targets for berberine and atherosclerosis were identified, respectively. Then, we constructed berberine and atherosclerosis targets with PPI data. Berberine targets network with PPI data had 3204 nodes and 79437 edges. Atherosclerosis targets network with PPI data had 5451 nodes and 130891 edges. Furthermore, we merged the two PPI networks and obtained the core PPI network from the merged PPI network. The core PPI network had 132 nodes and 3339 edges. At last, we performed functional enrichment analyses including GO and KEGG pathway analysis in David database. GO analysis indicated that the biological processes were correlated with G1/S transition of mitotic cells cycle. KEGG pathway analysis found that the pathways directly associated with berberine against atherosclerosis were cell cycle, ubiquitin mediated proteolysis, MAPK signaling pathway, and PI3K-Akt signaling pathway. After combining the results in context with the available treatments for atherosclerosis, we considered that berberine inhibited inflammation and cell proliferation in the treatment of atherosclerosis. Our study provided a valid theoretical foundation for future research.http://dx.doi.org/10.1155/2020/3568756
collection DOAJ
language English
format Article
sources DOAJ
author Xuejiao Xie
Xingyu Ma
Siyu Zeng
Wansi Tang
Liucheng Xiao
Chenggong Zhu
Rong Yu
spellingShingle Xuejiao Xie
Xingyu Ma
Siyu Zeng
Wansi Tang
Liucheng Xiao
Chenggong Zhu
Rong Yu
Mechanisms of Berberine for the Treatment of Atherosclerosis Based on Network Pharmacology
Evidence-Based Complementary and Alternative Medicine
author_facet Xuejiao Xie
Xingyu Ma
Siyu Zeng
Wansi Tang
Liucheng Xiao
Chenggong Zhu
Rong Yu
author_sort Xuejiao Xie
title Mechanisms of Berberine for the Treatment of Atherosclerosis Based on Network Pharmacology
title_short Mechanisms of Berberine for the Treatment of Atherosclerosis Based on Network Pharmacology
title_full Mechanisms of Berberine for the Treatment of Atherosclerosis Based on Network Pharmacology
title_fullStr Mechanisms of Berberine for the Treatment of Atherosclerosis Based on Network Pharmacology
title_full_unstemmed Mechanisms of Berberine for the Treatment of Atherosclerosis Based on Network Pharmacology
title_sort mechanisms of berberine for the treatment of atherosclerosis based on network pharmacology
publisher Hindawi Limited
series Evidence-Based Complementary and Alternative Medicine
issn 1741-427X
1741-4288
publishDate 2020-01-01
description Atherosclerosis is a common metabolic disease characterized by lipid metabolic disorder. The processes of atherosclerosis include endothelial dysfunction, new endothelial layer formation, lipid sediment, foam cell formation, plaque formation, and plaque burst. Owing to the adverse effects of first-line medications, it is urgent to discover new medications to deal with atherosclerosis. Berberine is one of the most promising natural products derived from traditional Chinese medicine. However, the panoramic mechanism of berberine against atherosclerosis has not been discovered clearly. In this study, we used network pharmacology to investigate the interaction between berberine and atherosclerosis. We identified potential targets related to berberine and atherosclerosis from several databases. A total of 31 and 331 putative targets for berberine and atherosclerosis were identified, respectively. Then, we constructed berberine and atherosclerosis targets with PPI data. Berberine targets network with PPI data had 3204 nodes and 79437 edges. Atherosclerosis targets network with PPI data had 5451 nodes and 130891 edges. Furthermore, we merged the two PPI networks and obtained the core PPI network from the merged PPI network. The core PPI network had 132 nodes and 3339 edges. At last, we performed functional enrichment analyses including GO and KEGG pathway analysis in David database. GO analysis indicated that the biological processes were correlated with G1/S transition of mitotic cells cycle. KEGG pathway analysis found that the pathways directly associated with berberine against atherosclerosis were cell cycle, ubiquitin mediated proteolysis, MAPK signaling pathway, and PI3K-Akt signaling pathway. After combining the results in context with the available treatments for atherosclerosis, we considered that berberine inhibited inflammation and cell proliferation in the treatment of atherosclerosis. Our study provided a valid theoretical foundation for future research.
url http://dx.doi.org/10.1155/2020/3568756
work_keys_str_mv AT xuejiaoxie mechanismsofberberineforthetreatmentofatherosclerosisbasedonnetworkpharmacology
AT xingyuma mechanismsofberberineforthetreatmentofatherosclerosisbasedonnetworkpharmacology
AT siyuzeng mechanismsofberberineforthetreatmentofatherosclerosisbasedonnetworkpharmacology
AT wansitang mechanismsofberberineforthetreatmentofatherosclerosisbasedonnetworkpharmacology
AT liuchengxiao mechanismsofberberineforthetreatmentofatherosclerosisbasedonnetworkpharmacology
AT chenggongzhu mechanismsofberberineforthetreatmentofatherosclerosisbasedonnetworkpharmacology
AT rongyu mechanismsofberberineforthetreatmentofatherosclerosisbasedonnetworkpharmacology
_version_ 1715417275218001920